AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis , failed to meet the main goal of ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The CARDIO-TTRansform Phase III trial 1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy ...
Ionis Pharmaceuticals draws attention after a rare-disease therapy license agreement, keeping its RNA-targeted medicine ...
Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction June 24, ...
After 35 years of research and development in pharmaceutical products, Ionis began marketing its drugs for the first time in 2024. While the company’s maiden voyage into commercialization has ...
Ionis Pharmaceuticals has offloaded regional rights to its near-approval rare disease asset zilganersen, pocketing $30 million upfront from Recordati for an ex-U.S. license to the drug candidate.
Two years after its first approval for an ultra-rare lipid disorder, Ionis' Tryngolza has been approved by the FDA for severe hypertriglyceridaemia (sHTG), a much larger patient population, which is ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results